|
|||
|
A Meta-Analysis of Long- Versus Short-Acting Phosphodiesterase 5 Inhibitors: Comparing Combination Use With α-Blockers and α-Blocker Monotherapy for Lower Urinary Tract Symptoms and Erectile Dysfunction
Hoon Choi, Hyun Jung Kim, Jae Hyun Bae, Jae Heon Kim, Du Geon Moon, Jun Cheon, Jeong-Kyun Yeo
Int Neurourol J. 2015;19(4):237-245. Published online 2015 Dec 28
DOI: https://doi.org/10.5213/inj.2015.19.4.237 |
|||
|
Citations to this article as recorded by  Combination Alpha Blocker and Phosphodiesterase 5 Inhibitor Versus Alpha-Blocker Monotherapy for Lower Urinary Tract Symptoms Associated with Benign Prostate Hyperplasia
Po-Cheng Chen, Chung-Cheng Wang, Yu-Kang Tu
Urological Science.2020; 31(3): 99. CrossRef Erectile Dysfunction: An Umbrella Review of Meta-Analyses of Risk-Factors, Treatment, and Prevalence Outcomes
Mark S. Allen, Emma E. Walter
The Journal of Sexual Medicine.2019; 16(4): 531. CrossRef BPO/LUTS – Aktuelles zur medikamentösen Therapie
Thomas Burtscher, Jasmin Bektic
Journal für Urologie und Urogynäkologie/Österreich.2019; 26(4): 114. CrossRef Solifenacin and Tamsulosin Combination Therapy Decreases Urine Nerve Growth Factor/Creatinine Levels in Men
Robert Chan, Alvaro Munoz, Evan P. Wenker, Melissa Whipple, Brian Miles, Timothy B. Boone
Urology.2016; 91: 150. CrossRef Biased α-adrenergic receptor and βarrestin signaling in a cell culture model of benign prostatic hyperplasia
Mindy Wang, Yehia Daaka, Anindya Dey
Biochemical and Biophysical Research Communications.2016; 471(1): 41. CrossRef
|
